Ryuji Kubota

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Junichi Azuma, Masako Ohno, Ryuji Kubota et al. · European Journal of Clinical Pharmacology · 2012 · 273 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Antimicrobial Agents and Chemotherapy · 2022 · 69 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2

Ryuji Kubota, Masako Ohno, Tomoko Hasunuma et al. · European Journal of Clinical Pharmacology · 2007 · 40 citations

Medicine, Pharmacology, Pharmacotherapy +9

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Clinical Drug Investigation · 2023 · 38 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Clinical Drug Investigation · 2023 · 23 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17